JPRN-UMIN000036377招募中2 期
Evaluation of efficacy and safety of dose-escalating lenalidomide and dexamethasone (Ld) therapy and adapted therapy adding elotuzumab with insufficient efficacy by Ld therapy in newly diagnosed, transplant ineligible multiple myeloma patients (DELAYED study) - Evaluation of efficacy and safety of dose-escalating lenalidomide and dexamethasone (Ld) therapy and adapted therapy adding elotuzumab with insufficient efficacy by Ld therapy in newly diagnosed, transplant ineligible multiple myeloma patients (DELAYED study)
Gifu university hospital0 个研究点目标入组 33 人开始时间: 2019年4月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •3) CNS involvement 4) Serologically positive for HIVAb 5) Active malignancy concomitantly existed 6) Pregnant, possible pregnant, or breastfeeding woman 7) Severe infection or clinical complication 8) Severe mental disorder 9) Deep vein thrombosis or pulmonary thrombosis 10) Incompatibility of Lenalidomide, Dexamethasone and Elotuzumab 11) Patients who have been judged by the investigator to be inappropriate for participation in this clinical trial for other reasons.
研究者
相似试验
已完成
不适用
Dose-escalation study to evaluate safety and gastrointestinal tolerability of allulose in subjects compared to placeboHealthy subjectsDRKS00017848Pfeifer & Langen GmbH & Co. KG49
进行中（未招募）
1 期
Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination with Different Treatment Regimens in Subjects with Advanced Solid Tumors (Phase 1b/2; Protocol No. P04722) - N/AColorectal Adenocarcinoma, Non-small Cell Lung Cancer, Gastric Adenocarcinoma, Her2+ Breast Cancer, Renal Cell Cancer, Pancreatic AdenocarcinomaMedDRA version: 12.0 Level: LLT Classification code 10001150 Term: Adenocarcinoma gastricMedDRA version: 12.0 Level: LLT Classification code 10065430 Term: HER-2 positive breast cancerMedDRA version: 12.0 Level: LLT Classification code 10038407 Term: Renal cell cancerMedDRA version: 12.0 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinomaMedDRA version: 12.0 Level: PT Classification code 10052360 Term: <Manually entered code. Term in E.1.1>MedDRA version: 12.0 Level: PT Classification code 10061873 Term: <Manually entered code. Term in E.1.1>EUCTR2009-011101-16-GBSchering-Plough Research Institute, A Division of Schering Corporation250
已完成
不适用
Evaluation of efficacy of dose escalation strategy for treatment with sorafenib for hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000009126Kanazawa Medical University20
招募中
1 期
PHASE-I CLINICAL TRIAL OF INHALED FORMULATIONS OF LIFEVIROTREAT.CTRI/2021/04/033295Supreme Industries India
招募中
不适用
Dose escalation trial to evaluate the safety and the efficacy on new bone formation of a single local treatment with lithium carbonate to teeth extraction sockets for dental implant in Japanese participantsJPRN-UMIN000008795Kyushu University Hospital12